Article info
PDFClinical and epidemiological research
Extended report
Repeated administration of dapirolizumab pegol in a randomised phase I study is well tolerated and accompanied by improvements in several composite measures of systemic lupus erythematosus disease activity and changes in whole blood transcriptomic profiles
- Correspondence to Professor Chris Chamberlain, UCB Pharma, 208 Bath Road, Slough SL1 3WE, UK; Chris.Chamberlain{at}ucb.com
Citation
Repeated administration of dapirolizumab pegol in a randomised phase I study is well tolerated and accompanied by improvements in several composite measures of systemic lupus erythematosus disease activity and changes in whole blood transcriptomic profiles
Publication history
- Received November 1, 2017
- Revised June 1, 2017
- Accepted June 10, 2017
- First published August 5, 2017.
Online issue publication
January 09, 2022
Article Versions
- Previous version (9 January 2022).
- Previous version (9 January 2022).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2017. All rights reserved. No commercial use is permitted unless otherwise expressly granted.